Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease
Ji Young Yun, Han-Joon Kim, Jee-Young Lee, Young Eun Kim, Ji Seon Kim, Jong-Min Kim, Beom S Jeon, Ji Young Yun, Han-Joon Kim, Jee-Young Lee, Young Eun Kim, Ji Seon Kim, Jong-Min Kim, Beom S Jeon
Abstract
Background: Ropinirole prolonged release (RPR) is a once-daily formulation. However, there may be individual pharmacokinetic differences so that multiple dosing may be preferred in some individuals. This study compares once-daily and twice-daily RPR in patients with Parkinson's disease.
Methods: This study was an open-label crossover study. We enrolled Parkinson's disease patients on dopamine agonist therapy with unsatisfactory control such as motor fluctuation, dyskinesia and sleep-related problems. Agonists were switched into equivalent dose of RPR. Subjects were consecutively enrolled into either once-daily first or twice-daily first groups, and received the same amount of RPR in a single and two divided dosing for 8 weeks respectively in a crossover manner without a washout period.The primary outcome was a questionnaire of the preference completed by patients in the last visit. The secondary outcome measures included the Unified Parkinson's Disease Rating Scale part 3 (mUPDRS), Hoehn and Yahr stage (H&Y); sleep questionnaire including overall quality of sleep, nocturnal off symptoms and early morning symptoms; Epworth Sleep Scale (ESS); compliances and patient global impression (PGI).
Results: A total of 82 patients were enrolled and 61 completed the study. 31 patients preferred twice-daily regimen, 17 preferred the once-daily regimen, and 13 had no preference. Their mean mUPDRS, H&Y, ESS, sleep quality, compliance and adverse events were not statistically different in both regimens. PGI-improvement on wearing off defined was better in twice-daily dosing regimen.
Conclusions: RPR is a once-daily formulation, but multiple dosing was preferred in many patients. Multiple dosing of RPR might be a therapeutic option if once-daily dosing is unsatisfactory.
Trial registration: ClinicalTrials.gov NCT00986245.
Figures
References
- Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson’s disease. Neurology. 2000;55(11 Suppl 4):S13–S20. discussion S21-13.
- Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease PDMSI. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008;24(10):2883–2895. doi: 10.1185/03007990802387130.
- Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord. 2011;26(7):1259–1265. doi: 10.1002/mds.23498.
- Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L. et al.Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009;24(6):826–832. doi: 10.1002/mds.22112.
- Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson’s disease. Clin Ther. 2007;29(12):2654–2666. doi: 10.1016/j.clinthera.2007.12.010.
- Jost WH, Buhmann C, Fuchs G, Greulich W, Hummel S, Korchounov A, Mungersdorf M, Schwarz M, Spiegel-Meixensberger M. Initial experience with ropinirole PR (prolonged release) J Neurol. 2008;255(Suppl 5):60–63.
- Onofrj M, Bonanni L, De Angelis MV, Anzellotti F, Ciccocioppo F, Thomas A. Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies. Parkinsonism Relat Disord. 2009;15(Suppl 4):S85–S92.
Source: PubMed